TNF and rheumatoid arthritis: The resulting ORAL Surveillance Study, which was published in January 2022, found that tofacitinib was associated with significantly higher rates of major adverse cardiovascular events, cancers, and opportunistic infections compared with tumor necrosis factor inhibitors (TNFi) in RA patients ≥50 years with ≥1 cardiovascular risk factor (2).